Posted by Michael Wonder on 14 Jun 2023
Brukinsa gets reimbursement to treat rare blood cancer patients
2 May 2023 - Beigene Korea said Monday that its Brukinsa 80 mg capsules (zanubrutinib) began to receive insurance benefits to treat Waldenstrom's macroglobulinaemia starting this month.
The new reimbursement standard applies to Brukinsa’s monotherapy in adult Waldenstrom's macroglobulinaemia patients who have received one or more treatments.
